AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer
Shots:
- Study depicted a 28% reduction in the death risk with OS rates of 87.5% vs 83.2%, IDFS rates of 79.6% vs 70.3% & DDFS rates of 83.5% vs 75.7% at 6.1yrs. It also showed a 35% risk reduction in invasive breast cancer recurrence, second cancers or death as well as in distant disease recurrence or death
- The P-III (OlympiA) study assessed safety & efficacy of Lynparza vs PBO as a 12mos. adj. treatment of gBRCAm HER2-ve early breast cancer (n=1836) in those who completed neoadjuvant or adjuvant CT also published in NEJM
- Safety aligned with prior trials, with no new concerns or increased risk of myelodysplastic syndrome or AML
Ref: AstraZeneca and Merck | Image: AstraZeneca and Merck
Related News:- AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
